Related Experiment Video

Updated: May 1, 2026

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.6K

The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer

Luc Friboulet1,2, Nanxin Li3, Ryohei Katayama1,2,4

  • 1Massachusetts General Hospital Cancer Center, Boston, MA 02129, USA.

Cancer Discovery
|March 29, 2014
PubMed
Abstract

Insights

Ceritinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, effectively overcomes resistance to crizotinib in non-small cell lung cancer (NSCLC) models. It shows potent inhibition against most crizotinib-resistant ALK mutations, supporting its clinical efficacy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Anaplastic lymphoma kinase (ALK) gene rearrangements drive non-small cell lung cancer (NSCLC) growth.
  • Resistance to the first-generation ALK tyrosine kinase inhibitor (TKI), crizotinib, is inevitable in ALK-rearranged NSCLC.
  • Next-generation ALK TKIs are needed to overcome acquired resistance.

Purpose of the Study:

  • To evaluate the preclinical efficacy of ceritinib, a next-generation ALK TKI, against crizotinib-resistant NSCLC.
  • To identify specific ALK mutations overcome by ceritinib.
  • To provide a molecular basis for ceritinib's clinical activity in resistant NSCLC.

Main Methods:

  • In vitro and in vivo studies using cell lines and patient-derived xenografts.
  • Testing ceritinib against NSCLC models with acquired resistance to crizotinib.
  • Cocrystal structure analysis of ceritinib bound to ALK.

Main Results:

  • Ceritinib potently inhibited NSCLC cells with acquired resistance to crizotinib.
  • Ceritinib effectively overcame key ALK mutations including L1196M, G1269A, I1171T, and S1206Y.
  • Ceritinib did not overcome ALK mutations G1202R and F1174C, which were found in resistant patient samples.

Conclusions:

  • Ceritinib demonstrates potent activity against a range of crizotinib-resistant ALK mutations.
  • The findings support ceritinib as an effective treatment for patients with ALK-positive NSCLC resistant to crizotinib.
  • Structural insights explain ceritinib's potency against specific resistant mutations.

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.0K
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

19.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
689